Abstract
Hodgkin lymphoma (HL) is a relatively rare malignancy, occurring in the United States (US) at approximately 1/20th the rate of lung cancer, and 1/7th the rate of non-Hodgkin lymphoma in 2006 [1]. Yet, it has inspired a high degree of scientific interest because of the heterogeneity of its clinical presentation and behavior, with some aspects characteristic of malignancy but others recalling an infectious process; the complexity of its histology, including the infrequent malignant Hodgkin Reed–Sternberg (HRS) cell in an otherwise normal reactive infiltrate, and the variability of cell surface markers [2]; and its unusual occurrence in children and young adults, in whom it is one of the most common cancers [1], as well as in older persons. Motivated by these characteristics and MacMahon’s seminal papers on the epidemiology of HL in 1957 and 1966 [3, 4], epidemiologists have worked to disentangle the complexity of this disease so as to arrive at a clear understanding of its pathogenesis and etiology. However, even as findings from this research have helped elucidate some aspects of HL etiology, they have continued to reveal significant epidemiologic heterogeneity across patient groups that recalls the disease’s clinical and pathologic complexity. This heterogeneity complicates the interpretation of epidemiologic research conducted for HL as a single entity and perhaps challenges the classification of what is currently categorized as HL. Indeed, in 1999, HL was split into two main groups – classical HL, which comprises the majority of the subtypes, and lymphocyte-predominant HL, an uncommon disease considered a B-cell lymphoma despite HRS cell presence [5]. Regardless, the central feature of classical HL epidemiology is the very consistent observation of heterogeneity in its occurrence and risk factors.
Keywords
- Human Leukocyte Antigen
- Hodgkin Lymphoma
- Infectious Mononucleosis
- Classical Hodgkin Lymphoma
- Mixed Cellularity
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- CI:
-
Confidence interval
- COX:
-
Cyclooxygenase
- EA:
-
Early antigen
- EBNA:
-
Epstein–Barr nuclear antigen
- EBV:
-
Epstein–Barr virus
- HL:
-
Hodgkin lymphoma
- HLA:
-
Human leukocyte antigen
- HRS:
-
Hodgkin Reed–Sternberg
- IL:
-
Interleukin
- IM:
-
Infectious mononucleosis
- OR:
-
Odds ratio
- RR:
-
Relative risk
- SEER:
-
Surveillance, Epidemiology, and End Results
- SES:
-
Socioeconomic status
- US:
-
United States
- UVR:
-
Ultraviolet radiation
- VCA:
-
Viral capsid antigen
References
Homer MJ, Ries LAG, Krapcho M, et al., editors. SEER Cancer Statistics Review, 1975-2006. Bethesda, MD: National Cancer Institute; 2009.
Mani H, Jaffe ES. Hodgkin lymphoma: An update on its biology with new insights into classification. Clin Lymph Res. 2009;9:206–16.
MacMahon B. Epidemiological evidence on the nature of Hodgkin’s disease. Cancer. 1957;10:1045–54.
MacMahon B. Epidemiology of Hodgkin’s disease. Cancer Res. 1966;26(6):1189–201.
Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997 [see comments]. J Clin Oncol. 1999;17(12):3835–49.
Ferlay J, Bray F, Pisani P, et al. GLOBOCAN 2002: Cancer incidence, mortality and prevalence worldwide. In: IARC CancerBase No 5 version 20. Lyon: IARC Press; 2004.
Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence – SEER 17 Regs Limited-Use + Hurricane Katrina Impacted Louisiana Cases, Nov 2008 Sub (2000-2006) <Katrina/Rita Population Adjustment> – Linked To County Attributes - Total U.S., 1969–2006 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2009, based on the November 2008 submission.
Reed DM. On the pathological changes in Hodgkin’s disease, with especial reference to its relation to tuberculosis. Johns Hopkins Hosp Rep. 1902;10:133–396.
Correa P, O’Conor GT. Epidemiologic patterns of Hodgkin’s disease. Int J Cancer. 1971;8(2):192–201.
Macfarlane G, Evstifeeva T, Boyle P, et al. International patterns in the occurrence of Hodgkin’s disease in children and young adult males. Int J Cancer. 1995;61(2):165–9.
Hjalgrim H, Seow A, Rostgaard K, et al. Changing patterns of Hodgkin lymphoma incidence in Singapore. Int J Cancer. 2008;123(3):716–9.
Glaser SL, Hsu JL. Hodgkin’s disease in Asians: incidence patterns and risk factors in population-based data. Leuk Res. 2002;26:261–9.
Au WY, Gascoyne RD, Gallagher RE, et al. Hodgkin’s lymphoma in Chinese migrants to British Columbia: a 25-year survey. Ann Oncol. 2004;15(4):626–30.
Caporaso NE, Goldin LR, Anderson WF, et al. Current insight on trends, causes, and mechanisms of Hodgkin’s lymphoma. Cancer J. 2009;15:117–23.
Clarke CA, Glaser SL, Keegan THM, et al. Neighborhood socioeconomic status and Hodgkin lymphoma incidence in California. Cancer Epidemiol Biomark Prev. 2005;14:1441–7.
Chen YT, Zheng T, Mei-Chu C, et al. The increase in Hodgkin’s disease incidence among young adults. Experience in Connecticut, 1935–1992. Cancer. 1997;79:2209–18.
Gutensohn N, Cole P. Epidemiology of Hodgkin’s disease in the young. Int J Cancer. 1977;19(5):595–604.
Cozen W, Katz J, Mack TM. Risk patterns of Hodgkin’s disease in Los Angeles vary by cell type. Cancer Epidemiol Biomark Prev. 1992;1(4):261–8.
Glaser SL. Regional variation in Hodgkin’s disease incidence by histologic subtype in the US. Cancer. 1987;60:2841–7.
Grufferman S, Delzell E. Epidemiology of Hodgkin’s disease. Epidemiol Rev. 1984;6:76–106.
Abramson JH, Pridan H, Sacks MI, et al. A case-control study of Hodgkin’s disease in Israel. J Natl Cancer Inst. 1978;61:307–14.
Bernard SM, Cartwright RA, Darwin CM, et al. Hodgkin’s disease: case control epidemiological study in Yorkshire. Br J Cancer. 1987;55(1):85–90.
Cohen BM, Smetana HF, Miller RW. Hodgkin’s disease: Long survival in a study of 388 World War II army cases. Cancer. 1964;17:856–66.
Glaser SL, Clarke CA, Nugent RA, et al. Social class and risk of Hodgkin’s disease in young-adult women in 1988-94. Int J Cancer. 2002;98:110–7.
Gutensohn N, Cole P. Childhood social environment and Hodgkin’s disease. New Engl J Med. 1981;304:135–40.
Serraino D, Franceschi S, Talamini R, et al. Socio-economic indicators, infectious diseases and Hodgkin’s disease. Int J Cancer. 1991;47:352–7.
Alexander FE, Ricketts TJ, McKinney PA, et al. Community lifestyle characteristics and incidence of Hodgkin’s disease in young people. Int J Cancer. 1991;48(1):10–4.
Bonelli L, Vitale V, Bistolfi F, et al. Hodgkin’s disease in adults: association with social factors and age at tonsillectomy. A case-control study. Int J Cancer. 1990;45(3):423–7.
Chang ET, Montgomery SM, Richiardi L, et al. Number of siblings and risk of Hodgkin’s lymphoma. Cancer Epidemiol Biomark Prev. 2004;13(7):1236–43.
Chang ET, Zheng T, Weir EG, et al. Childhood social environment and Hodgkin’s lymphoma: new findings from a population-based case-control study. Cancer Epidemiol Biomark Prev. 2004;13(8):1361–70.
Westergaard T, Melbye M, Pedersen JB, et al. Birth order, sibship size and risk of Hodgkin’s disease in children and young adults: a population-based study of 31 million person-years. Int J Cancer. 1997;72:977–81.
Carter CD, Brown Jr TM, Herbert JT, et al. Cancer incidence following infectious mononucleosis. Am J Epidemiol. 1977;105(1):30–6.
Connelly RR, Christine BW. A cohort study of cancer following infectious mononucleosis. Cancer Res. 1974;34(5):1172–8.
Hjalgrim H, Askling J, Sorensen P, et al. Risk of Hodgkin’s disease and other cancers after infectious mononucleosis. J Natl Cancer Inst. 2000;92(18):1522–8.
Hjalgrim H, Askling J, Rostgaard K, et al. Characteristics of Hodgkin’s lymphoma after infectious mononucleosis. N Engl J Med. 2003;349:1324–32.
Hjalgrim H, Smedby KE, Rostgaard K, et al. Infectious mononucleosis, childhood social environment, and risk of Hodgkin lymphoma. Cancer Res. 2007;67:2382–8.
Kvåle G, Høiby EA, Pedersen E. Hodgkin’s disease in patients with previous infectious mononucleosis. Int J Cancer. 1979;23:593–7.
Miller RW, Beebe GW. Infectious mononucleosis and the empirical risk of cancer. J Natl Cancer Inst. 1973;50:315–21.
Rosdahl N, Larsen SO, Thamdrup AB. Infectious mononucleosis in Denmark. Epidemiological observations based on positive Paul-Bunnell reactions from 1940-1969. Scand J Infect Dis. 1973;5(3):163–70.
Gutensohn NM. Social class and age at diagnosis of Hodgkin’s disease: new epidemiologic evidence for the “two-disease hypothesis”. Cancer Treat Rep. 1982;66(4):689–95.
Gutensohn NM, Shapiro DS. Social class risk factors among children with Hodgkin’s disease. Int J Cancer. 1982;30(4):433–5.
Glaser SL, Clarke CA, Stearns CB, et al. Age variation in Hodgkin’s disease risk factors in older women: evidence from a population-based case-control study. Leuk Lymphoma. 2001;42:997–1004.
IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Epstein-Barr virus and Kaposi’s sarcoma herpesvirus/human herpesvirus8, vol. 7. Lyon: International Agency for Research on Cancer; 1997.
Evans AS, Gutensohn NM. A population-based case-control study of EBV and other viral antibodies among persons with Hodgkin’s disease and their siblings. Int J Cancer. 1984;34:149–57.
Mueller N, Evans A, Harris NL, et al. Hodgkin’s disease and Epstein-Barr virus. Altered antibody pattern before diagnosis. N Engl J Med. 1989;320(11):689–95.
Weiss LM, Movahed LA, Warnke RA, et al. Detection of Epstein-Barr viral genomes in Reed-Sternberg cells of Hodgkin’s disease. N Engl J Med. 1989;320:502–6.
Glaser SL, Lin RJ, Stewart SL, et al. Epstein-Barr virus-associated Hodgkin’s disease: epidemiologic characteristics in international data. Int J Cancer. 1997;70:375–82.
Jarrett RF. Risk factors for Hodgkin’s lymphoma by EBV status and significance of detection of EBV genomes in serum of patients with EBV-associated Hodgkin’s lymphoma. Leuk Lymphoma. 2003;44 Suppl 3:S27–32.
Glaser SL, Gulley ML, Clarke CA, et al. Racial/ethnic variation in EBV-positive classical Hodgkin lymphoma in California populations. Int J Cancer. 2008;123:1499–507.
Jarrett RF, Krajewski AS, Angus B, et al. The Scotland and Newcastle epidemiological study of Hodgkin’s disease: impact of histopathological review and EBV status on incidence estimates. J Clin Pathol. 2003;56:811–6.
Alexander FE, Lawrence DJ, Freeland J, et al. An epidemiologic study of index and family infectious mononucleosis and adult Hodgkin’s disease (HD): evidence for a specific association with EBV+ve HD in young adults. Int J Cancer. 2003;107(2):298–302.
Cozen W, Hamilton AS, Zhao P, et al. A protective role for early oral exposures in the etiology of young adult Hodgkin lymphoma. Blood. 2009;114(19):4014–20.
Glaser SL, Keegan THM, Clarke CA, et al. Exposure to childhood infections and risk of EBV-defined Hodgkin’s lymphoma in women. Int J Cancer. 2005;115:599–605.
Montella M, Maso LD, Crispo A, et al. Do childhood diseases affect NHL and HL risk? A case-control study from northern and southern Italy. Leuk Res. 2006;30(8):917–22.
Newton R, Crouch S, Ansell P, et al. Hodgkin’s lymphoma and infection: findings from a UK case-control study. Br J Cancer. 2007;97(9):1310–4.
Sleckman BG, Mauch PM, Ambinder RF, et al. Epstein-Barr virus in Hodgkin’s disease: correlation of risk factors and disease characteristics with molecular evidence of viral infection. Cancer Epidemiol Biomark Prev. 1998;7:1117–21.
Chang ET, Zheng T, Lennette ET, et al. Heterogeneity of risk factors and antibody profiles in Epstein-barr virus genome-positive and -negative Hodgkin lymphoma. J Infect Dis. 2004;189:2271–81.
Jarrett RF. Viruses and Hodgkin’s lymphoma. Ann Oncol. 2002;13 Suppl 1:23–9.
Hors J, Steinberg G, Andrieu JM, et al. HLA genotypes in familial Hodgkin’s disease. Excess of HLA identical affected sibs. Eur J Cancer. 1980;16(6):809–15.
Lin AY, Kingma DW, Lennette ET, et al. Epstein-Barr virus and familial Hodgkin’s disease. Blood. 1996;88(8):3160–5.
Bjerrum OW, Hasselbalch HC, Drivsholm A, et al. Non-Hodgkin malignant lymphomas and Hodgkin’s disease in first-degree relatives. Evidence for a mutual genetic predisposition? Scand J Haematol. 1986;36(4):398–401.
Donhuijsen-Ant R, Abken H, Bornkamm G, et al. Fatal Hodgkin and non-Hodgkin lymphoma associated with persistent Epstein-Barr virus in four brothers. Ann Intern Med. 1988;109(12):946–52.
Goldin LR, Pfeiffer RM, Gridley G, et al. Familial aggregation of Hodgkin lymphoma and related tumors. Cancer. 2004;100:1902–8.
Lynch HT, Marcus JN, Weisenburger DD, et al. Genetic and immunopathological findings in a lymphoma family. Br J Cancer. 1989;59(4):622–6.
Padua L, Palmisani MT, Di Trapani G, et al. Myasthenia gravis and thymic Hodgkin’s disease associated in one patient with familial lymphoproliferative disorders. Clin Neuropathol. 1994;13(5):292–4.
Razis DV, Diamond HD, Craver LF. Familial Hodgkin’s disease: its significance and implications. Ann Intern Med. 1959;51(5):933–71.
Buehler SK, Firme F, Fodor G, et al. Common variable immunodeficiency, Hodgkin’s disease, and other malignancies in a Newfoundland family. Lancet. 1975;1(7900):195–7.
Grufferman S, Ambinder RF, Shugart YY, et al. Increased cancer risk in families of children with Hodgkin’s disease. Am J Epidemiol. 1998;147(11):S8.
Lynch HT, Marcus JN, Lynch JF. Genetics of Hodgkin’s and non-Hodgkin’s lymphoma: a review. Cancer Invest. 1992;10(3):247–56.
McKeen EA, Mulvihill JJ, Levine PH, et al. The concurrence of Saethre-Chotzen syndrome and malignancy in a family with in vitro immune dysfunction. Cancer. 1984;54(12):2946–51.
Chakravarti A, Halloran SL, Bale SJ, et al. Etiological heterogeneity in Hodgkin’s disease: HLA linked and unlinked determinants of susceptibility independent of histological concordance. Genet Epidemiol. 1986;3(6):407–15.
Haim N, Cohen Y, Robinson E. Malignant lymphoma in first-degree blood relatives. Cancer. 1982;49(10):2197–200.
Mack TM, Cozen W, Shibata DK, et al. Concordance for Hodgkin’s disease in identical twins suggesting genetic susceptibility to the young-adult form of the disease. N Engl J Med. 1995;332:413–8.
Brown JR, Neuberg D, Phillips K, et al. Prevalence of familial malignancy in a prospectively screened cohort of patients with lymphoproliferative disorders. Br J Haematol. 2008;143(3):361–8.
Chang ET, Smedby KE, Hjalgrim H, et al. Family history of hematopoietic malignancy and risk of lymphoma. J Natl Cancer Inst. 2005;97(19):1466–74.
Friedman DL, Kadan-Lottick NS, Whitton J, et al. Increased risk of cancer among siblings of long-term childhood cancer survivors: a report from the Childhood Cancer Survivor Study. Cancer Epidemiol Biomark Prev. 2005;14(8):1922–7.
Goldgar DE, Easton DF, Cannon-Albright LA, et al. Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands. J Natl Cancer Inst. 1994;86:1600–8.
Grufferman S, Cole P, Smith PG, et al. Hodgkin’s disease in siblings. N Engl J Med. 1977;296(5):248–50.
Hemminki K, Czene K. Attributable risks of familial cancer from the Family-Cancer Database. Cancer Epidemiol Biomark Prev. 2002;11:1638–44.
Kerzin-Storrar L, Faed MJ, MacGillivray JB, et al. Incidence of familial Hodgkin’s disease. Br J Cancer. 1983;47(5):707–12.
McDuffie H, Pahwa P, Karunanayake C, et al. Clustering of cancer among families of cases with Hodgkin Lymphoma (HL), Multiple Myeloma (MM), Non-Hodgkin’s Lymphoma (NHL), Soft Tissue Sarcoma (STS) and control subjects. BMC Cancer. 2009;9(1):70.
Pang D, Alston RD, Eden TOB, et al. Cancer risks among relatives of children with Hodgkin and non-Hodgkin lymphoma. Int J Cancer. 2008;123(6):1407–10.
Rudant J, Menegaux F, Leverger G, et al. Family history of cancer in children with acute leukemia, Hodgkin’s lymphoma or non-Hodgkin’s lymphoma: the ESCALE study (SFCE). Int J Cancer. 2007;121(1):119–26.
Casey R, Brennan P, Becker N, et al. Influence of familial cancer history on lymphoid neoplasms risk validated in the large European case-control study epilymph. Eur J Cancer. 2006;42(15):2570–6.
Chatterjee N, Hartge P, Cerhan JR, et al. Risk of non-Hodgkin’s lymphoma and family history of lymphatic, hematologic, and other cancers. Cancer Epidemiol Biomark Prev. 2004;13(9):1415–21.
Wang SS, Slager SL, Brennan P, et al. Family history of hematopoietic malignancies and risk of non-Hodgkin lymphoma (NHL): a pooled analysis of 10 211 cases and 11 905 controls from the International Lymphoma Epidemiology Consortium (InterLymph). Blood. 2007;109(8):3479–88.
Altieri A, Hemminki K. The familial risk of Hodgkin’s lymphoma ranks among the highest in the Swedish Family-Cancer Database. Leukemia. 2006;20(11):2062–3.
Paltiel O, Schmit T, Adler B, et al. The incidence of lymphoma in first-degree relatives of patients with Hodgkin disease and non-Hodgkin lymphoma: results and limitations of a registry-linked study. Cancer. 2000;88(10):2357–66.
Shugart YY, Hemminki K, Vaittinen P, et al. Apparent anticipation and heterogeneous transmission patterns in familial Hodgkin’s and non-Hodgkin’s lymphoma: report from a study based on Swedish cancer database. Leuk Lymphoma. 2001;42:407–15.
Daugherty SE, Pfeiffer RM, Mellemkjaer L, et al. No evidence for anticipation in lymphoproliferative tumors in population-based samples. Cancer Epidemiol Biomark Prev. 2005;14(5):1245–50.
Goldin LR, Björkholm M, Kristinsson SY, et al. Highly increased familial risks for specific lymphoma subtypes. Br J Haematol. 2009;146(1):91–4.
Hemminki K, Li X. Familial risk in testicular cancer as a clue to a heritable and environmental aetiology. Br J Cancer. 2004;90(9):1765–70.
Hjalgrim H, Rasmussen S, Rostgaard K, et al. Familial clustering of Hodgkin lymphoma and multiple sclerosis. J Natl Cancer Inst. 2004;96(10):780–4.
Landgren O, Kerstann KF, Gridley G, et al. Re: Familial clustering of Hodgkin lymphoma and multiple sclerosis. J Natl Cancer Inst. 2005;97(7):543–4.
Goldin LR, McMaster ML, Ter-Minassian M, et al. A genome screen of families at high risk for Hodgkin lymphoma: evidence for a susceptibility gene on chromosome 4. J Med Genet. 2005;42:595–601.
Hemminki K, Li X, Czene K. Familial risk of cancer: data for clinical counseling and cancer genetics. Int J Cancer. 2004;108:109–14.
Hemminki K, Li X. Cancer risks in twins: results from the Swedish family-cancer database. Int J Cancer. 2002;99(6):873–8.
Swerdlow AJ, De Stavola B, Maconochie N, et al. A population-based study of cancer risk in twins: relationships to birth order and sexes of the twin pair. Int J Cancer. 1996;67(4):472–8.
Horwitz M, Wiernik PH. Pseudoautosomal linkage of Hodgkin disease. Am J Hum Genet. 1999;65(5):1413–22.
Horwitz MS, Mealiffe ME. Further evidence for a pseudoautosomal gene for Hodgkin’s lymphoma: Reply to “The familial risk of Hodgkin’s lymphoma ranks among the highest in the Swedish Family-Cancer Database” by Altieri A and Hemminki K. Leukemia. 2006;21(2):351.
Kamper PM, Kjeldsen E, Clausen N, et al. Epstein-Barr virus-associated familial Hodgkin lymphoma: paediatric onset in three of five siblings. Br J Haematol. 2005;129(5):615–7.
Mueller NE, Grufferman S. Hodgkin lymphoma. In: Schottenfeld D, Fraumeni JF, editors. Cancer epidemiology and prevention. 3rd ed. New York: Oxford University Press; 2006. p. 872–97.
Rowlings PA, Curtis RE, Passweg JR, et al. Increased incidence of Hodgkin’s disease after allogeneic bone marrow transplantation. J Clin Oncol. 1999;17(10):3122–7.
Frisch M, Biggar RJ, Engels EA, et al. Association of cancer with AIDS-related immunosuppression in adults. JAMA. 2001;285(13):1736–45.
Berenguer J, Miralles P, Ribera JM, et al. Characteristics and outcome of AIDS-related Hodgkin lymphoma before and after the introduction of highly active antiretroviral therapy. JAIDS. 2008;47(4):422–8.
Biggar RJ, Jaffe ES, Goedert JJ, et al. Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS. Blood. 2006;108(12):3786–91.
Engels EA, Pfeiffer RM, Goedert JJ, et al. Trends in cancer risk among people with AIDS in the United States 1980–2002. AIDS. 2006;20(12):1645–54.
Baker KS, DeFor TE, Burns LJ, et al. New malignancies after blood or marrow stem-cell transplantation in children and adults: incidence and risk factors. J Clin Oncol. 2003;21(7):1352–8.
Smedby KE, Baecklund E, Askling J. Malignant lymphomas in autoimmunity and inflammation: a review of risks, risk factors, and lymphoma characteristics. Cancer Epidemiol Biomark Prev. 2006;15:2069–77.
Kristinsson SY, Landgren O, Sjoberg J, et al. Autoimmunity and risk for Hodgkin’s lymphoma by subtype. Haematologica. 2009;94(10):1468–9.
Anderson LA, Gadalla S, Morton LM, et al. Population-based study of autoimmune conditions and the risk of specific lymphoid malignancies. Int J Cancer. 2009;125:398–405.
Eguchi K. Apoptosis in autoimmune diseases. Intern Med. 2001;40:275–84.
Cozen W, Gill PS, Salam MT, et al. Interleukin-2, interleukin-12, and interferon-{gamma} levels and risk of young adult Hodgkin lymphoma. Blood. 2008;111(7):3377–82.
Biggar RJ, Johansen JS, Ekström Smedby K, et al. Serum YKL-40 and interleukin 6 levels in Hodgkin lymphoma. Clin Cancer Res. 2008;14(21):6974–8.
Cozen W, Gill PS, Ingles SA, et al. IL-6 levels and genotype are associated with risk of young adult Hodgkin lymphoma. Blood. 2004;103(8):3216–21.
Gause A, Scholz R, Klein S, et al. Increased levels of circulating interleukin-6 in patients with Hodgkin’s disease. Hematol Oncol. 1991;9(6):307–13.
Gause A, Keymis S, Scholz R, et al. Increased levels of circulating cytokines in patients with untreated Hodgkin’s disease. Lymphokine Cytokine Res. 1992;11(2):109–13.
Herling M, Rassidakis GZ, Medeiros LJ, et al. Expression of Epstein-Barr virus latent membrane protein-1 in Hodgkin and Reed-Sternberg cells of classical Hodgkin’s lymphoma: associations with presenting features, serum interleukin 10 levels, and clinical outcome. Clin Cancer Res. 2003;9(6):2114–20.
Hohaus S, Giachelia M, Massini G, et al. Clinical significance of interleukin-10 gene polymorphisms and plasma levels in Hodgkin lymphoma. Leuk Res. 2009;33(10):1352–6.
Niens M, Visser L, Nolte IM, et al. Serum chemokine levels in Hodgkin lymphoma patients: highly increased levels of CCL17 and CCL22. Br J Haematol. 2008;140(5):527–36.
Chang ET, Zheng T, Weir EG, et al. Aspirin and the risk of Hodgkin’s lymphoma in a population-based case-control study. J Natl Cancer Inst. 2004;96:305–15.
Chang ET, Cronin-Fenton DP, Friis S, et al. Aspirin and other nonsteroidal anti-inflammatory drugs in relation to Hodgkin lymphoma risk in northern Denmark. Cancer Epidemiol Biomark Prev. 2010;19:59–64.
Baeuerle PA, Baltimore D. NF-kappa B: ten years after. Cell. 1996;87(1):13–20.
Yamamoto Y, Yin MJ, Lin KM, et al. Sulindac inhibits activation of the NF-kappaB pathway. J Biol Chem. 1999;274(38):27307–14.
Bargou RC, Leng C, Krappmann D, et al. High-level nuclear NF-kappa B and Oct-2 is a common feature of cultured Hodgkin/Reed-Sternberg cells. Blood. 1996;87(10):4340–7.
Bargou RC, Emmerich F, Krappmann D, et al. Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin’s disease tumor cells. J Clin Invest. 1997;100(12):2961–9.
Hinz M, Loser P, Mathas S, et al. Constitutive NF-kappaB maintains high expression of a characteristic gene network, including CD40, CD86, and a set of antiapoptotic genes in Hodgkin/Reed-Sternberg cells. Blood. 2001;97(9):2798–807.
Izban KF, Ergin M, Huang Q, et al. Characterization of NF-kappaB expression in Hodgkin’s disease: inhibition of constitutively expressed NF-kappaB results in spontaneous caspase-independent apoptosis in Hodgkin and Reed-Sternberg cells. Mod Pathol. 2001;14(4):297–310.
Van Der Ouderaa FJ, Buytenhek M, Nugteren DH, et al. Acetylation of prostaglandin endoperoxide synthetase with acetylsalicylic acid. Eur J Biochem. 1980;109(1):1–8.
Goodwin JS, Messner RP, Bankhurst AD, et al. Prostaglandin-producing suppressor cells in Hodgkin’s disease. N Engl J Med. 1977;297(18):963–8.
Hsu SM, Hsu PL, Lo SS, et al. Expression of prostaglandin H synthase (cyclooxygenase) in Hodgkin’s mononuclear and Reed-Sternberg cells. Functional resemblance between H-RS cells and histiocytes or interdigitating reticulum cells. Am J Pathol. 1988;133(1):5–12.
Diepstra A, Niens M, te Meerman GJ, et al. Genetic susceptibility to Hodgkin’s lymphoma associated with the human leukocyte antigen region. Eur J Haematol Suppl. 2005;75(66):34–41.
Berberich FR, Berberich MS, King MC, et al. Hodgkin’s disease susceptibility: linkage to the HLA locus demonstrated by a new concordance method. Hum Immunol. 1983;6:207–17.
Harty LC, Lin AY, Goldstein AM, et al. HLA-DR, HLA-DQ, and TAP genes in familial Hodgkin disease. Blood. 2002;99:690–3.
Lynch HT, Saldivar VA, Guirgis HA, et al. Familial Hodgkin’s disease and associated cancer. Cancer. 1976;38:2033–41.
Hors J, Dausset J. HLA and susceptibility to Hodgkin’s disease. Immunol Rev. 1983;70:167–92.
Paltiel O. Family matters in Hodgkin lymphoma. Leuk Lymph. 2008;49(7):1234–5.
Shugart YY, Hemminki K, Vaittinen P, et al. A genetic study of Hodgkin’s lymphoma: an estimate of heritability and anticipation based on the familial cancer database in Sweden. Hum Genet. 2000;106:553–6.
Ahmad T, Neville M, Marshall SE, et al. Haplotype-specific linkage disequilibrium patterns define the genetic topography of the human MHC. Hum Mol Genet. 2003;12(6):647–56.
Liang X, Caporaso N, McMaster ML, et al. Common genetic variants in candidate genes and risk of familial lymphoid malignancies. Br J Haematol. 2009;146(4):418–23.
da Silva GN, Bacchi MM, Rainho CA, et al. Epstein-Barr virus infection and single nucleotide polymorphisms in the promoter region of interleukin 10 gene in patients with Hodgkin lymphoma. Arch Pathol Lab Med. 2007;131:1691–6.
Chang ET, Birmann BM, Kasperzyk JL, et al. Polymorphic variation in NFKB1 and other aspirin-related genes and risk of Hodgkin lymphoma. Cancer Epidemiol Biomark Prev. 2009;18(3):976–86.
Baecklund E, Iliadou A, Askling J, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum. 2006;54:692–701.
Bodmer JG, Tonks S, Oza AM, et al. HLA-DP based resistance to Hodgkin’s disease. Lancet. 1989;333(8652):1455–6.
Oza AM, Tonks S, Lim J, et al. A clinical and epidemiological study of human leukocyte antigen-DPB alleles in Hodgkin’s disease. Cancer Res. 1994;54(19):5101–5.
Taylor GM, Gokhale DA, Crowther D, et al. Increased frequency of HLA-DPB1*0301 in Hodgkin’s disease suggests that susceptibility is HVR-sequence and subtype-associated. Leukemia. 1996;10:854–9.
Taylor GM, Gokhale DA, Crowther D, et al. Further investigation of the role of HLA-DPB1 in adult Hodgkin’s disease (HD) suggests an influence on susceptibility to different HD subtypes. Br J Cancer. 1999;80:1405–11.
Klitz W, Aldrich CL, Fildes N, et al. Localization of predisposition to Hodgkin disease in the HLA class II region. Am J Hum Genet. 1994;54(3):497–505.
Alexander FE, Jarrett RF, Cartwright RA, et al. Epstein-Barr Virus and HLA-DPB1-*0301 in young adult Hodgkin’s disease: evidence for inherited susceptibility to Epstein-Barr Virus in cases that are EBV(+ve). Cancer Epidemiol Biomark Prev. 2001;10:705–9.
Diepstra A, Niens M, Vellenga E, et al. Association with HLA class I in Epstein-Barr-virus-positive and with HLA class III in Epstein-Barr-virus-negative Hodgkin’s lymphoma. Lancet. 2005;365:2216–24.
Niens M, van den Berg A, Diepstra A, et al. The human leukocyte antigen class I region is associated with EBV-positive Hodgkin’s lymphoma: HLA-A and HLA complex group 9 are putative candidate genes. Cancer Epidemiol Biomark Prev. 2006;15:2280–4.
Niens M, Jarrett RF, Hepkema B, et al. HLA-A*02 is associated with a reduced risk and HLA-A*01 with an increased risk of developing EBV-positive Hodgkin lymphoma. Blood. 2007;110:3310–5.
McAulay KA, Higgins CD, Macsween KF, et al. HLA class I polymorphisms are associated with development of infectious mononucleosis upon primary EBV infection. J Clin Invest. 2007;117:3042–8.
Briggs NC, Hall HI, Brann EA, et al. Cigarette smoking and risk of Hodgkin’s disease: a population-based case-control study. Am J Epidemiol. 2002;156:1011–20.
Besson H, Brennan P, Becker N, et al. Tobacco smoking, alcohol drinking and Hodgkin’s lymphoma: a European multi-centre case-control study (EPILYMPH). Br J Cancer. 2006;95(3):378–84.
Glaser SL, Keegan TH, Clarke CA, et al. Smoking and Hodgkin lymphoma risk in women United States. Cancer Causes Control. 2004;15(4):387–97.
Hjalgrim H, Ekström-Smedby K, Rostgaard K, et al. Cigarette smoking and risk of Hodgkin lymphoma: a population-based case-control study. Cancer Epidemiol Biomark Prev. 2007;16:1561–6.
Klatsky AL, Li Y, Baer D, et al. Alcohol consumption and risk of hematologic malignancies. Ann Epidemiol. 2009;19(10):746–53.
Lim U, Morton LM, Subar AF, et al. Alcohol, smoking, and body size in relation to incident Hodgkin’s and non-Hodgkin’s lymphoma risk. Am J Epidemiol. 2007;166(6):697–708.
Nieters A, Deeg B, Becker N. Tobacco and alcohol consumption and risk of lymphoma: results of a population-based case-control study in Germany. Int J Cancer. 2006;118(2):422–30.
Nieters A, Rohrmann S, Becker N, et al. Smoking and lymphoma risk in the European Prospective Investigation into Cancer and Nutrition. Am J Epidemiol. 2008;167(9):1081–9.
Willett EV, O’Connor S, Smith AG, et al. Does smoking or alcohol modify the risk of Epstein-Barr Virus-positive or -negative Hodgkin lymphoma? Epidemiology. 2007;18(1):130–6.
Sopori ML, Kozak W. Immunomodulatory effects of cigarette smoke. J Neuroimmunol. 1998;83(1–2):148–56.
Gorini G, Stagnaro E, Fontana V, et al. Alcohol consumption and risk of Hodgkin’s lymphoma and multiple myeloma: a multicentre case-control study. Ann Oncol. 2007;18(1):143–8.
Kanda J, Matsuo K, Kawase T, et al. Association of alcohol intake and smoking with malignant lymphoma risk in Japanese: a hospital-based case-control study at Aichi Cancer Center. Cancer Epidemiol Biomark Prev. 2009;18(9):2436–41.
Monnereau A, Orsi L, Troussard X, et al. Cigarette smoking, alcohol drinking, and risk of lymphoid neoplasms: results of a French case–control study. Cancer Causes Control. 2008;19(10):1147–60.
Tavani A, Pregnolato A, Negri E, et al. Diet and risk of lymphoid neoplasms and soft tissue sarcomas. Nutr Cancer. 1997;27(3):256–60.
Bobrove AM. Alcohol-related pain and Hodgkin’s disease. West J Med. 1983;138(6):874–5.
Diaz LE, Montero A, Gonzalez-Gross M, et al. Influence of alcohol consumption on immunological status: a review. Eur J Clin Nutr. 2002;56 Suppl 3:S50–3.
Ekström Smedby K, Hjalgrim H, Melbye M, et al. Ultraviolet radiation exposure and risk of malignant lymphomas. J Natl Cancer Inst. 2005;97(3):199–209.
Grandin L, Orsi L, Troussard X, et al. UV radiation exposure, skin type and lymphoid malignancies: results of a French case-control study. Cancer Causes Control. 2008;19(3):305–15.
Boffetta P, van der Hel O, Kricker A, et al. Exposure to ultraviolet radiation and risk of malignant lymphoma and multiple myeloma – a multicentre European case-control study. Int J Epidemiol. 2008;37(5):1080–94.
Guyton KZ, Kensler TW, Posner GH. Vitamin D and vitamin D analogs as cancer chemopreventive agents. Nutr Rev. 2003;61(7):227–38.
Hickish T, Cunningham D, Colston K, et al. The effect of 1, 25-dihydroxyvitamin D3 on lymphoma cell lines and expression of vitamin D receptor in lymphoma. Br J Cancer. 1993;68(4):668–72.
Chen S, Sims GP, Chen XX, et al. Modulatory effects of 1, 25-dihydroxyvitamin D3 on human B cell differentiation. J Immunol. 2007;179(3):1634–47.
Isager H, Andersen E. Pre-morbid factors in Hodgkin’s disease. I. Birth weight and growth pattern from 8 to 14 years of age. Scand J Haematol. 1978;21:250–5.
Hancock BW, Mosely R, Coup AJ. Height and Hodgkin’s disease (letter). Lancet. 1976;2:1364.
Keegan THM, Glaser SL, Clarke CA, et al. Body size, physical activity and risk of Hodgkin lymphoma in women. Cancer Epidemiol Biomark Prev. 2006;15:1095–101.
La Vecchia C, Negri E, Parazzini F, et al. Height and cancer risk in a network of case-control studies from northern Italy. Int J Cancer. 1990;45(2):275–9.
Paffenbarger Jr RS, Wing AL, Hyde RT. Characteristics in youth indicative of adult-onset Hodgkin’s disease. J Natl Cancer Inst. 1977;58(5):1489–91.
Willett EV, Roman E. Obesity and the risk of Hodgkin lymphoma (United Kingdom). Cancer Causes Control. 2006;17:1103–6.
Gunnell D, Okasha M, Smith GD, et al. Height, leg length, and cancer risk: a systematic review. Epidemiol Rev. 2001;23(2):313–42.
Silventoinen K. Determinants of variation in adult body height. J Biosoc Sci. 2003;35(2):263–85.
Mueller N. Hodgkin’s disease. In: Schottenfeld D, Fraumeni Jr JF, editors. Cancer epidemiology and prevention. 2nd ed. New York, NY: Oxford University Press; 1996. p. 893–919.
Mueller N, Grufferman S. The epidemiology of Hodgkin’s disease. In: Mauch PM, Armitage JO, Diehl V, et al., editors. Hodgkin’s disease. Philadelphia: Lippincott Williams & Wilkins; 1999. p. 61–77.
Okasha M, Gunnell D, Holly J, et al. Childhood growth and adult cancer. Best Pract Res Clin Endocrinol Metab. 2002;16(2):225–41.
Wolk A, Gridley G, Svensson M, et al. A prospective study of obesity and cancer risk (Sweden). Cancer Causes Control. 2001;12(1):13–21.
Bosetti C, Dal Maso L, Negri E, et al. Re: Body mass index and risk of malignant lymphoma in Scandinavian men and women. J Natl Cancer Inst. 2005;97(11):860–1.
Chang ET, Hjalgrim H, Smedby KE, et al. Body mass index and risk of malignant lymphoma in Scandinavian men and women. J Natl Cancer Inst. 2005;97(3):210–8.
Bianchini F, Kaaks R, Vainio H. Overweight, obesity, and cancer risk. Lancet Oncol. 2002;3(9):565–74.
Glaser SL. Reproductive factors in Hodgkin’s disease in women: a review. Am J Epidemiol. 1994;139:237–46.
Kravdal O, Hansen S. Hodgkin’s disease: The protective effect of childbearing. Int J Cancer. 1993;55:909–14.
Kravdal O, Hansen S. The importance of childbearing for Hodgkin’s disease: new evidence from incidence and mortality models. Int J Epidemiol. 1996;25(4):737–43.
Lambe M, Hsieh CC, Tsaih S-W, et al. Childbearing and the risk of Hodgkin’s disease. Cancer Epidemiol Biomark Prev. 1998;7:831–4.
Tavani A, Pregnolato A, La Vecchia C, et al. A case-control study of reproductive factors and risk of lymphomas and myelomas. Leuk Res. 1997;21:885–8.
Zwitter M, Zakelj MP, Kosmelj K. A case-control study of Hodgkin’s disease and pregnancy. Br J Cancer. 1996;73:246–51.
Glaser SL, Clarke CA, Nugent RA, et al. Reproductive risk factors in Hodgkin’s disease in women. Am J Epidemiol. 2003;158:553–63.
Hjalgrim H, Engels EA. Infectious aetiology of Hodgkin and non-Hodgkin lymphomas: a review of the epidemiological evidence. J Int Medicine. 2008;264(6):537–48.
Acknowledgments
The authors thank Kari Fish, Sarah Shema, and June Kristine Winters for help with this chapter. The collection of cancer incidence data used in this chapter was supported by the California Department of Health Services as part of the statewide cancer reporting program mandated by California Health and Safety Code Section 103885; the National Cancer Institute’s Surveillance, Epidemiology and End Results Program under contract N01-PC-35136 awarded to the Northern California Cancer Center (now the Cancer Prevention Institute of California), contract N01-PC-35139 awarded to the University of Southern California, and contract N02-PC-15105 awarded to the Public Health Institute; and the Centers for Disease Control and Prevention’s National Program of Cancer Registries, under agreement #U55/CCR921930-02 awarded to the Public Health Institute. The ideas and opinions expressed herein are those of the authors and endorsement by the State of California, Department of Health Services, the National Cancer Institute, and the Centers for Disease Control and Prevention or their contractors and subcontractors is not intended nor should be inferred.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Glaser, S.L., Chang, E.T., Clarke, C.A., Keegan, T.H. (2011). Epidemiology. In: Engert, A., Horning, S. (eds) Hodgkin Lymphoma. Hematologic Malignancies. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-12780-9_1
Download citation
DOI: https://doi.org/10.1007/978-3-642-12780-9_1
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-12779-3
Online ISBN: 978-3-642-12780-9
eBook Packages: MedicineMedicine (R0)